198 related articles for article (PubMed ID: 29068290)
21. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
Nguyen CM; Leon A; Danesh M; Beroukhim K; Wu JJ; Koo J
J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
[TBL] [Abstract][Full Text] [Related]
22. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Schafer P
Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
[TBL] [Abstract][Full Text] [Related]
24. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
[TBL] [Abstract][Full Text] [Related]
25. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
26. Real-world use of apremilast for patients with psoriasis in Japan.
Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
[TBL] [Abstract][Full Text] [Related]
27. Three cases of palmoplantar pustulosis successfully treated with apremilast.
Eto A; Nakao M; Furue M
J Dermatol; 2019 Jan; 46(1):e29-e30. PubMed ID: 29905386
[No Abstract] [Full Text] [Related]
28. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
Paller AS; Hong Y; Becker EM; de Lucas R; Paris M; Zhang W; Zhang Z; Barcellona C; Maes P; Fiorillo L
J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
[TBL] [Abstract][Full Text] [Related]
29. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
Pathan E; Abraham S; Van Rossen E; Withrington R; Keat A; Charles PJ; Paterson E; Chowdhury M; McClinton C; Taylor PC
Ann Rheum Dis; 2013 Sep; 72(9):1475-80. PubMed ID: 22984171
[TBL] [Abstract][Full Text] [Related]
31. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.
Garcet S; Nograles K; Correa da Rosa J; Schafer PH; Krueger JG
J Allergy Clin Immunol; 2018 Sep; 142(3):1010-1013.e6. PubMed ID: 29936103
[No Abstract] [Full Text] [Related]
32. ▼ Apremilast for psoriasis and psoriatic arthritis.
Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
[TBL] [Abstract][Full Text] [Related]
33. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
[TBL] [Abstract][Full Text] [Related]
35. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Moustafa F; Feldman SR
Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
[TBL] [Abstract][Full Text] [Related]
36. Psoriasis improvement and satisfaction in patients using a clobetasol spray and oral apremilast combination regimen: A pilot study.
Wei C; Friedman AJ; Prussick RB
J Am Acad Dermatol; 2020 Oct; 83(4):1198-1200. PubMed ID: 32088274
[No Abstract] [Full Text] [Related]
37. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Yiu ZZ; Warren RB
Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
[TBL] [Abstract][Full Text] [Related]
38. Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.
Wong TH; Sinclair S; Smith B; Fraser C; Morton CA
Clin Exp Dermatol; 2017 Aug; 42(6):675-676. PubMed ID: 28621002
[No Abstract] [Full Text] [Related]
39. Apremilast as a treatment for psoriasis.
Shutty B; West C; Pellerin M; Feldman S
Expert Opin Pharmacother; 2012 Aug; 13(12):1761-70. PubMed ID: 22712800
[TBL] [Abstract][Full Text] [Related]
40. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
J Comp Eff Res; 2020 Aug; 9(11):767-779. PubMed ID: 32638609
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
